In the early stage of COVID-19, some patients with normal hepatic biochemical parameters (alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transferase, and total bilirubin) experience progression to liver dysfunction (LD) after the initiation of hepatotoxic-antiviral drugs, with even dramatic progression to liver failure without predictable circumstances (Carothers et al, 2020; Weber et al, 2020). This evidence concerns the gene GPT and COVID-19.